Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002262 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002262: Completed Phase 1 study, sponsored by University of California, San Francisco.
NCT00002262 is a Phase 1 study that has completed, run by University of California, San Francisco. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002262, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections. In addition, to assess the effects of TNF injections on Kaposi's sarcoma (KS) lesions as measured by P-32 magnetic resonance spectroscopy.
Interventions
- DRUG Tumor Necrosis Factor
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002262 record still lists
NCT00002262 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Tumor Necrosis Factor is the first listed.
NCT00002262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002262 about?
NCT00002262 is a clinical study titled "A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma". To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections. In addition, to assess the effects of TNF injections on Kaposi's sarcoma (KS) ...
What is the current status of trial NCT00002262?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002262?
The interventions under investigation include: Tumor Necrosis Factor (DRUG).
Who is sponsoring clinical trial NCT00002262?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.